CARM (CARISMA Therapeutics) Scaled Net Operating Assets: -0.58 (As of Sep. 2025)


What is CARISMA Therapeutics Scaled Net Operating Assets?

CARISMA Therapeutics CARM -27.16% Scaled Net Operating Assets is -0.58 as of Sep. 2025. The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CARISMA Therapeutics's operating assets for the quarter that ended in Sep. 2025 was $3.78 Mil. CARISMA Therapeutics's operating liabilities for the quarter that ended in Sep. 2025 was $6.66 Mil. CARISMA Therapeutics's Total Assets for the quarter that ended in Jun. 2025 was $5.01 Mil. Therefore, CARISMA Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2025 was -0.58.

CARISMA Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Scaled Net Operating Assets Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
0.03 0.00 -4.36 -0.67 -0.48

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.59 -1.03 -1.38 -2.90 -0.58

CARM vs SCPX, CYTOF, CNBX: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Scaled Net Operating Assets falls into.


CARISMA Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

CARISMA Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(12.549-55.886)/89.554
=-0.48

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=30.458 - 17.909
=12.549

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=58.367 - 0.744 - 1.737
=55.886

CARISMA Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2025 )
=(Operating Assets (Q: Sep. 2025 )-Operating Liabilities (Q: Sep. 2025 ))/Total Assets (Q: Jun. 2025 )
=(3.777-6.659)/5.012
=-0.58

where

Operating Assets(Q: Sep. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6.554 - 2.777
=3.777

Operating Liabilities(Q: Sep. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=7.421 - 0.609 - 0.153
=6.659

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.58 mean?
CARISMA Therapeutics (CARM) has a Scaled Net Operating Assets of -0.58 as of Sep. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' Scaled Net Operating Assets too high?
CARISMA Therapeutics' current Scaled Net Operating Assets is -0.58.
How does CARISMA Therapeutics' Scaled Net Operating Assets compare to SCPX and CYTOF?
CARISMA Therapeutics' Scaled Net Operating Assets of -0.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Scaled Net Operating Assets is -0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Scaled Net Operating Assets is -0.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Scaled Net Operating Assets is -0.58 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.